Please try another search
For the nine months ended 31 March 2017, Aoxing Pharmaceutical Company Inc revenues decreased 9% to $21.3M. Net income applicable to common stockholders decreased 89% to $435K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects General and administrative expenses increase from $2.7M to $5.6M (expense).
Period Ending: | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Revenue | 5.7 | 8.01 | 7.57 | 8.82 |
Gross Profit | 4.42 | 6.3 | 6.05 | 6.16 |
Operating Income | 0.88 | 0.23 | 1.7 | -1.85 |
Net Income | 0.13 | -0.04 | 0.35 | -1.9 |
Period Ending: | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Total Assets | 62.47 | 58.72 | 58.77 | 56.23 |
Total Liabilities | 43.36 | 39.88 | 39.24 | 37.1 |
Total Equity | 19.11 | 18.84 | 19.53 | 19.14 |
Period Ending: | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -2.79 | 0.22 | 0.13 | -0.53 |
Cash From Investing Activities | -0.01 | -0.01 | -0 | -0.12 |
Cash From Financing Activities | 3.18 | 0 | 0 | 2.95 |
Net Change in Cash | 0.17 | -0.06 | 0.14 | 1.54 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review